New Proteomics Analysis May Show How Ivermectin Fights COVID-19

New Proteomics Analysis May Show How Ivermectin Fights COVID-19

A new article in the Journal of Cellular Physiology from September 22 looks at a real-world problem: while we do have some evidence that ivermectin is useful for COVID-19, the mechanism by which the drug works has been less clear. Noting that ivermectin inhibits SARS-CoV-2 replication in vitro, the authors sought to locate ivermectin-related virus-pathway alterations using human cancel cells. The method focused on “quantitative proteomics;” the proteome is all the proteins made by an organism, and proteomics is the large-scale study of proteins. This study purports to be the, “first to provide ivermectin‐regulated virus‐related pathways by SILAC (Stable isotope labeling by amino acids in cell culture) quantitative proteomics analysis, which revealed a broad‐spectrum antiviral property of ivermectin.” Also, the ivermectin-regulated proteins included SARS-CoV-2-related proteins, and this might help in using ivermectin-related biomarkers in treating COVID-19. The authors expect their results to, “guide efforts to understand the molecular mechanisms underlying ivermectin used for the treatment of SARS‐CoV‐2 infection.”

TrialSite News Insights

The study essentially “tagged” the ivermectin molecules, so researchers could track their journey and activity when subjected to a variety of pathogens. It showed antiviral activity against both HIV and COVID-19. Even more, it seemed to have anti-inflammatory/immunosuppressive properties which likely help with the “cytokine storm.” Importantly, before this study “naysayers” could point to a lack of evidence for ivermectin mechanisms against COVID-19. The journal article is an effective rebuttal to these views. 


This site uses Akismet to reduce spam. Learn how your comment data is processed.

  1. Something new I learned that vaccines for covid will have to be retaken every 3 months because the antibodies or whatever makes them work only last that long. I heard Dr Rajters success with ivermectin was a dose like the one used to treat scabies so the Monash study was unnecessarily high. Also vitamin D3 is showing to be low in the people that are seriously in trouble with covid.

  2. More data on the specific MOA’s for Ivermectin are informative on how and when during Covid-19 it might have utility. At this point, with the plethora of RWE coupled with the excellent safety profile of this drug off label usage should be widely available for any patient after a detailed discussion with their physician regarding the limitations of the scientific evidence, the potential risks and any contraindications specific to their case. Not sure why Ivermectin has seen such a steep uphill battle against off label prescribing when 20% of all prescriptions are off label in the US.